Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM1 sodium injection for acute ischemic stroke
CTR20202440Phase 4Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of monosialotetrahexosylganglioside in ischemic stroke, sponsored by Qilu Pharmaceutical. Started Dec 2020; status: completed.
02
Drugs
monosialotetrahexosylganglioside
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on CTR20202440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202440.